BGB-290-103 : A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

One/TwoPhase One/Two

18-99Age 18-99

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Breast,Female reproductive organs,Lung,Stomach and upper gastrointestinal tract,Urinary systemBreast,Gastro-oesophageal junction ,Lung,Oesophagus,Ovary,Prostate,Small Cell Lung Cancer,Stomach

Trial Overview Read MoreRead more

This phase I/II trial is evaluating a new drug (BGB-290) in combination with an oral chemotherapy drug (Temozolomide) in patients with locally advanced or metastatic solid cancers.
 

This trial is treating patients with advanced solid cancers.

This is a systemic therapy trial.

You may be able to join this trial if:

  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors

Commercial Sponsor

BeiGene USA, Inc.

Summary

This is a non-randomised dose escalation and expansion study. Patients will be assigned to one of three arms. In Arm A (Dose Escalation) approximately 25 patients will receive continuous BGB-290 and TMZ on Days 1-7 of a 28 day cycle. In Arm B (Dose Escalation) approximately 25 patients will receive continuous BGB-290 and continuous TMZ on a 28 day cycle. In Arm C (Dose Expansion) approximately 100 patients will receive BGB-290 and TMZ at the recommended dose from the escalation phase.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Ms Marian Lieschke
marian.lieschke@petermac.org
03 8559 7140

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next